The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I don't believe for one minute that any small delay will need to be RNS'd. If the deal is off and that is still a possibility (despite what some on here say), then it needs an RNS. - and it is because of that possibility that the SP is still <40p.
There is also no way that we will see any real II action until everything is complete - fund managers cannot take a risk on something that has even a 10% chance of not getting the expected signatures. They would rather pay 80% more to get a 20% profit than risk having to answer to their clients as to why they bought before the deal was signed, sealed and delivered.
Now I firmly believe, as per my post a few days ago that everything is still pointing to a positive resolution and that in the next few trading days - tomorrow or early in the new year we shall hear the good news - but if it drags on another couple of weeks then so be it.
I think many missed Suzy's interview with Scott on BRR media just before Christmas - Suzy, from memory, discussed that the signatures were close, hopefully this year, if not very soon. She also talked about 2022, Val creating revenue and the options they have to bring on board another two potential game-changing (my words) compounds.
We are days, not months away from Val201 news - along with potential other transformational deals next year.
Although we were never informed officially of the period grated to TheoremRx to conduct their DD, we were told that Val expected the first payments by year end. Since taking over the CEO's role - Suzy has delivered and timeliness have nit slipped - i think it is close and that VRX will sign the Doc, followed by the first payments.
Val also tweaked and restated the Val201 license from CRT earlier this month at (I believe) the request of theoremRx, probably a perquisites to signing.
CRT have also been asked to approve (licence requirement) Val and TRX proceeding to full license - this wouldnt have happened if Theorem hadn't raised the funds and completed or were close to completing their due diligence .
All this, I believe, points towards the deal going through and first payments recieved - I personally think it will be be before Christmas and certainly before year end.
Great work Suzy and the team, have a well deserved festive break ready for another great year 2022.
D
Cat5, not sure what point you are making by highlighting the distance between BP licence and Hurricane's ???? most investors know or should know exactly where the acerage is.
Potatohead. Thats incorrect also - they do not need to make an offer for the highest price paid - only the highest price that they have paid for the shares - and that would include any bought from CA. CA certainly haven't paid over 5p for their shares in the last 12 months.
Sense men, not quite correct either as in most cases your 7p scenario would still count whether open market or not - but even if it did, the bidder would still need to convince a whole lot more shareholders to sell them their shares - going above the 30% threshold doesn't automatically entitle then to buy the remaining shares at any set price.
FWIW - I do not hold any here but still keep an interest for old times sake.
And those with DMA will likely be looking at the bigger picture. After the Avacta RNS, I thought bothe they and Abingdon H would rise minimum of 50% today - and they still might. It will need confirmation now of the orders to get this anywhere close to the IPO price of a quid. That said with the small MC, this could move fast.
I suggest that they are switching initially to PCR for air travel so they can differentiate between the Delta and the Omicron variants - as the LFTs do not.
Let's also hope that not only does the VISITECT test, but also the current Gov supplied LFT's, detect the new variant - if not then not only do the UK Gov have an issue (and a $hitload of even more useless chinese tests to bin), so will most other countries - and a load of Omicron "friendly" LFT's may be needed.
Who said the pandemic was over, this latest variant should show that a UK diagnostic capability is even more essential, unfortunately the UK Gov have fallen far short - if Boris and the DHSC do come back looking for capacity then I hope that UK manufacturers call the shots with decent contracts and legally binding guarantees going forward.
The very fact that ODX needed to take legal advice to find out if the contract had ended beggars belief, particularly as they were in "regular discussions with the DHSC" - I suggest that shows that the DHSC were just as clueless and were waiting for the UK Gov to make decisions on future LFT usage and policy.
Now with the new omicron variant everything is up in the air - no doubt policy will revert to target testing areas with LFT's where the new variant is detected, with any positives being confirmed by PCR. It may be that the free LFT's will be again extended, who knows. Was it this sort of scenario (plan B to secure or supplement the Chinese supplied plan A) that the contract was initially set up for? - possibly obviously the company and the DHSC have no idea, not even sure the UK Gov do.
I only watched the first half hour of the presentation (due to other commitments) and although Chris came across better than Colin, which wasn't hard, it does not make him ODX CEO material - what i though was interesting was when Chris mentioned and stressed on several occasions, his M&A experience with previous positions he has held !!!! FWIW, I am not calling for Colin to go, not yet anyway. - Colin is possibly naive and maybe lacking experience, and he certainly won't make a fortune on the after-dinner speaking circuit - but I don't think he is dishonest and I think changing CEO now would not do the company or the SP any favours.
Anyway, enjoy the rest of the weekend, I think that the ODX roller coaster ride has a few more surprises in store for us all - let's hope so :-)
Yep, and the directors all bought in at the placing price - the Company now have the funds that will attract the investments and contracts. Significantly over subscribed. :-). Just a shame that the allocation for current private investors is so low as I think this will be taken up fully - depending obviously where the SP is at the time.
Correct, we may also see investors or II's using this to build a position knowing that the Company are now fully funded for the next couple of years. It will also mean that they can now press ahead with the planning, FEED, JV's and debt to get the plants built.
Roy, it will depend on your broker but is relatively simple - that said, the shareprice will likely dip close or touch the placing price tomorrow so you should have no issue buying on the open Market. The way the SP dropped after the news suggests that a raise was expected so not a big deal here and should set a bottom of 8p to build on for the next "24 months". Sensible that they are raising at this level rather than where it was 6 months ago which would have resulted in a much larger dilution.
Jet2 MOU or news on funding needed to take those past this months recent highs of 17p. That said there are a load of other airlines that will need SAF to get anywhere near the regulations.
I still wonder if we will see some entity coming in with a T/O offer - the IP alone surely underpins the MC, and the Japanese have already had a very good look at it - including using VLS technology SAF (50% mix I believe) in a comercial flight.
Interesting times.
Convb, you really are a complete tit, no company will disclose commercially sensitive details on contracts like you are pretending you need- and why would they - the next Airline/producer will negotiate different terms and will not/should not be privy to that level of fetail on previous deals.
Now no one should be basing their trading decisions on BB losers posts, but it is well worth checking out posters history to get a jest of their agenda, some show they call it wrong time after time.
Or not as the case may be.
Deej, waiting till later may pay off, but those that procrastinated 2 days ago are paying a lot more. This is now big news in America at the top level and II's, possibly even large O&G Companies, will be looking at this over the next few days, even if just to get the Green tick in the box. A TR1 Monday morning showing one of the big boys taking a position would put a rocket under the SP.
Ells, shame you and a few other losers can't buy any because here are a few facts.
The deal is potentially worth over $60 mil to Val.
First payment due next month.
Monthly revenue from consultation services linked to the licensing agreement and to facilitate TT.
Fully funded this year and next year.
More deals to follow, possibly again with KS and Co.
Remember the backers, prior to releasing fund to TheoremRX, will also have done the DD on little old Val. With a sub - £25M MC they may like it too much.
Late December will be when we see the deal signed, sealed and delivered - those speculating that it will be earlier will be wrong.
Now although Suzi never categorically ruled out raising money, she did say that their was no need as they were funded through till 2023, and any raise would only be if something was offered that they couldn't turn down and only then if shareholders agreed - or words to that effect.A lot on here spouting nonsense both ways - far better to save the questions for Suzy and the team at the soonest to be announced Q&A session which will take place in the next week or so. -s o this can go two ways - 1 (most likely), the deal will be signed around 21st Dec, the SP hits 50p. or 2 (Unlikely, but possible), the deal is off and they walk away, the SP nose dives for a while and Suzy looks for another suitor. Risk reward here stacks up IMO, Q&A session will also clarify a few points no doubt.